Introduction: During Brachytherapy treatment organs in pelvic region can move because of the peristaltic or different bladder filling. The result are differencies between planned and absorbed doses to organs at risk. We evaluate dose to the organ at risk with dose volume histogram parameters D2cm3 and D0,1cm3. Purpose: The purpose of this study is to evaluate impact of intrafractional organ motion on absorbed dose in organs at risk in cervical carcinoma brachytherapy during pulse dose rate brachytherapy. Materials and methods: In this study 15 patient with locally advanced Cervical cancer, treated with pulse dose rate brachytheapy after external beam radiotherapy and chemotherapy were observed. Clinicaly approved treatment plans and control plans were used. All plans were magnetic resonance imaging - based. Control magnetic resonance imaging was done after pulse dose rate irradiation. Clinically approved and control magnetic resonance images for each patient were registred together with respect to the applicator. We evaluated and compared volumes, D2cm3 and D0,1cm3 values for the bladder, rectum, sigmoid bowel and small intestine. Results and discussion: In all cases differences between observed bladder and rectum volumes were found. No statistically significant differences were found between the volumes between two scans of organ at risks. No statistically significant differences were found between two plans for organ at risks D2cm3 and D0,1 cm3, except for D2cm3 for the rectum (p = 0,038). We found no large average differences, but there were some large variations in D2cm3 observed for individual patients, which should be take into account. Similar results were reported in literature by other authors. Conclusions: The results show that organ at risks volumes change during pulse dose rate brachytherapy treatment, which results in dose varaiations. Although we found no large average differences, there were some large variations in D2cm3 observed, which should be taken into account, especially when on clinicaly approved treatment plan doses are close to the planning constraints.
|